


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee  1. Reynolds Memorial Hospital, Inc.  2. 800 Wheeling Avenue Glen Dale, WV 26038-1697		In accordance with letter dated December 23, 2019.	4. Expiration Date: February 29, 2024
			5. Docket No.: 030-03384 Reference No.:
		3. License number: 47-08019-01 is amended in its entirety to read as follows:	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
 <b>CONDITIONS</b>			
10. Licensed material may be used or stored at the licensee's facilities located at 800 Wheeling Avenue, Glen Dale, West Virginia.			
11. The Radiation Safety Officer (RSO) for this license is Michael J. Maroney, M.D.			

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

47-08019-01

Docket or Reference Number

030-03384

Amendment No. 49

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized UsersMaterial and Use

Eric Roger Balzano, M.D.

10 CFR 35.100, 10 CFR 35.200

Mark L. Benson, M.D.

10 CFR 35.100, 10 CFR 35.200

Vincent James Caruso, M.D.

10 CFR 35.100, 10 CFR 35.200

John L. DeFilippo, M.D.

10 CFR 35.100, 10 CFR 35.200

Eric William Irwin, M.D.

10 CFR 35.100, 10 CFR 35.200

Carter A. Kenamond, M.D.

10 CFR 35.100, 10 CFR 35.200

Gary Loh, M.D.

10 CFR 35.100, 10 CFR 35.200

Michael J. Maroney, M.D.

10 CFR 35.100, 10 CFR 35.200

Michael L. Slaysman, M.D.

10 CFR 35.100, 10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

47-08019-01

Docket or Reference Number

030-03384

Amendment No. 49

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 12, 2013, except therapy use and 1st Floor Stress Lab [ML13274A191]
- B. Letter dated September 23, 2016 [ML16274A414]
- C. Email dated March 15, 2017 [ML17082A524]
- D. Letter dated February 26, 2020 [ML20064G118]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: March 4, 2020

By: \_\_\_\_\_

Penny Lanzisera  
Region 1